LTZ Therapeutics

About LTZ Therapeutics

LTZ Therapeutics is an immunotherapy-focused biotechnology company aiming to empower myeloid cells to address unmet clinical needs in cancer treatment. Their mission is to maximize drugability potential through reverse translational science and emerging biology of the tumor microenvironment, boosting anti-tumor immunity for improved clinical benefits.

Products & Services

Myeloid Engager Platform:A platform focused on direct engagement of myeloid cells with target cells, activating killing mechanisms like phagocytosis, stimulating minimal cytokine release to reset the tumor microenvironment, and supporting durable anti-tumor immune responses through T cell activation.

LTZ-301

Universal Myeloid Cell Engager (U-MCE™)

Specialties

Myeloid Engager Therapeutics Reverse Translational Science Tumor Microenvironment Biology Anti-Tumor Immunity Drug Discovery & Development immunotherapy oncology autoimmune diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Financing Round T: - FT: Financing Round	A: 38000000 MR: - FA: 38 million FAN: 38000000	D: 2026-05-06 FD: 2026-05-06	3 investors
2	RT: Series A T: - FT: Series A	A: 20000000 MR: - FA: over $20 million FAN: 20000000	D: 2024-07-30 FD: 2024-07-30	4 investors
3	RT: Pre-A+ Financing T: - FT: Pre-A+ Financing	A: 10000000 MR: - FA: over $10 million FAN: 10000000	D: 2023-05-31 FD: 2023-05-31	4 investors

Financing Round Latest

2026-05-06

$38.0M

3 investors (Pro only)

Series A 2024-07-30

$20.0M

Pre-A+ Financing 2023-05-31

$10.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News